248 related articles for article (PubMed ID: 8913484)
1. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
Moghazeh SL; Pan X; Arain T; Stover CK; Musser JM; Kreiswirth BN
Antimicrob Agents Chemother; 1996 Nov; 40(11):2655-7. PubMed ID: 8913484
[TBL] [Abstract][Full Text] [Related]
2. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
3. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.
Williams DL; Spring L; Collins L; Miller LP; Heifets LB; Gangadharam PR; Gillis TP
Antimicrob Agents Chemother; 1998 Jul; 42(7):1853-7. PubMed ID: 9661035
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis.
Park YK; Kim BJ; Ryu S; Kook YH; Choe YK; Bai GH; Kim SJ
Int J Tuberc Lung Dis; 2002 Feb; 6(2):166-70. PubMed ID: 11931418
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus.
Wichelhaus T; Schäfer V; Brade V; Böddinghaus B
J Antimicrob Chemother; 2001 Feb; 47(2):153-6. PubMed ID: 11157898
[TBL] [Abstract][Full Text] [Related]
6. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates.
Saribaş Z; Kocagöz T; Alp A; Günalp A
J Clin Microbiol; 2003 Feb; 41(2):816-8. PubMed ID: 12574290
[TBL] [Abstract][Full Text] [Related]
7. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
[TBL] [Abstract][Full Text] [Related]
8. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai.
Ahmad S; Mokaddas E; Fares E
Diagn Microbiol Infect Dis; 2002 Nov; 44(3):245-52. PubMed ID: 12493171
[TBL] [Abstract][Full Text] [Related]
9. Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse?
Wallis RS
Am J Respir Crit Care Med; 2005 Jul; 172(1):4-5. PubMed ID: 15980108
[No Abstract] [Full Text] [Related]
10. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T
Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585
[TBL] [Abstract][Full Text] [Related]
11. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
[TBL] [Abstract][Full Text] [Related]
12. Characterization of spontaneous, In vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv.
Morlock GP; Plikaytis BB; Crawford JT
Antimicrob Agents Chemother; 2000 Dec; 44(12):3298-301. PubMed ID: 11083630
[TBL] [Abstract][Full Text] [Related]
13. Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants.
Huitric E; Werngren J; Juréen P; Hoffner S
Antimicrob Agents Chemother; 2006 Aug; 50(8):2860-2. PubMed ID: 16870787
[TBL] [Abstract][Full Text] [Related]
14. Characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from the Middle East.
Ahmad S; Araj GF; Akbar PK; Fares E; Chugh TD; Mustafa AS
Diagn Microbiol Infect Dis; 2000 Dec; 38(4):227-32. PubMed ID: 11146248
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City.
Cooksey RC; Morlock GP; Glickman S; Crawford JT
J Clin Microbiol; 1997 May; 35(5):1281-3. PubMed ID: 9114427
[TBL] [Abstract][Full Text] [Related]
16. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
Mor N; Simon B; Heifets L
Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
[TBL] [Abstract][Full Text] [Related]
17. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F
Antimicrob Agents Chemother; 1996 Feb; 40(2):426-8. PubMed ID: 8834891
[TBL] [Abstract][Full Text] [Related]
18. rpoB gene mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis in northern Lima, Peru.
Shin SS; Naroditskaya V; Sloutsky A; Werner B; Timperi R; Bayona J; Farmer PE; Becerra MC
Microb Drug Resist; 2005; 11(1):26-30. PubMed ID: 15770091
[TBL] [Abstract][Full Text] [Related]
19. Line probe assay for rapid detection of mutations in the rpoB gene of Mycobacterium tuberculosis.
Liu YC; Huang TS; Huang WK
J Formos Med Assoc; 1999 Aug; 98(8):582-5. PubMed ID: 10502914
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay.
Hirano K; Abe C; Takahashi M
J Clin Microbiol; 1999 Aug; 37(8):2663-6. PubMed ID: 10405418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
